Acute Interstitial Nephritis and Checkpoint Inhibitor Therapy Single Center Experience of Management and Drug Rechallenge

被引:48
作者
Manohar, Sandhya [1 ]
Ghamrawi, Ranine [1 ]
Chengappa, Madhuri [5 ]
Goksu, Busra N. Bacik [6 ]
Kottschade, Lisa [2 ]
Finnes, Heidi [3 ]
Dronca, Roxana [7 ]
Leventakos, Konstantinos [2 ]
Herrmann, Joerg [4 ]
Herrmann, Sandra M. [1 ]
机构
[1] Mayo Clin, Div Nephrol & Hypertens, 200 First St SW, Rochester, MN 55902 USA
[2] Mayo Clin, Dept Med Oncol, Rochester, MN 55902 USA
[3] Mayo Clin, Dept Pharm, Rochester, MN 55902 USA
[4] Mayo Clin, Dept Cardiol, Rochester, MN 55902 USA
[5] Nazareth Hosp, Dept Internal Med, Philadelphia, PA USA
[6] Univ Texas Southwestern, Dept Psychiat, Dallas, TX USA
[7] Mayo Clin, Dept Med Oncol, Jacksonville, FL 32224 USA
来源
KIDNEY360 | 2020年 / 1卷 / 01期
关键词
Acute Kidney Injury and ICU Nephrology; Acute Interstitial Nephritis; Acute Kidney Injury; Biopsy; Cohort Studies; Creatinine; Immune check point-rechallenge; Immune checkpoint inhibitors; Immune-related adverse event; Immunotherapy; Kidney Function Tests; Pneumonia; Prednisone; Proton Pump Inhibitors; COMBINED NIVOLUMAB; RENAL-FUNCTION; ASSOCIATION; IPILIMUMAB; RECOVERY; FEATURES;
D O I
10.34067/KID.0000152019
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background The objective of this case cohort study was to describe our experience in the care of patients with immune checkpoint inhibitor-related acute interstitial nephritis (ICI-AIN) including rechallenge. Methods A descriptive case series of patients that received an ICI and had an AKI (defined as a >= 1.5-fold increase in serum creatinine) as an immune-related adverse event (irAE), with biopsy-proven or clinically suspected ICI-AIN from January 1, 2014 to December 1, 2018 at Mayo Clinic, Rochester. We studied details regarding diagnosis, clinical course, management, and outcomes of rechallenge of immunotherapy. Complete response (CR) was defined as return of kidney function back to baseline or < 0.3 mg/dl above baseline creatinine; partial response (PR) was defined as creatinine > 0.3 mg/dl from baseline, but less than twofold above the baseline by the end of steroid course. Results A total of 14 cases of biopsy-proven (35%) or clinically suspected (65%) ICI-AIN was identified. All patients had their ICI withheld and 12 patients received steroids. Steroid regimens were highly variable. The starting equivalent dose of prednisone was higher in those that had a CR versus a PR (median 0.77 mg/kg versus 0.66 mg/kg). Proton pump inhibitors (PPIs) were used in 11 patients and were stopped in eight (73%) patients at the time of the AKI event. A CR was seen in five (63%) of the eight patients who discontinued PPIs. Rechallenge was attempted in four of the 14 patients: three were successful with no recurrence of AKI, but one patient had recurrent AKI and fatal pneumonitis. Conclusions Careful review, withholding ICI and concomitant known AIN-inducing medications, along with prompt initial steroid management were the key in complete renal kidney recovery. A kidney biopsy should be strongly considered. Rechallenge of immunotherapy after a kidney irAE, although challenging, is possible and would need careful evaluation on an individual basis.
引用
收藏
页码:16 / 24
页数:9
相关论文
共 30 条
  • [1] Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports
    Abdel-Wahab, Noha
    Shah, Mohsin
    Suarez-Almazor, Maria E.
    [J]. PLOS ONE, 2016, 11 (07):
  • [2] Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis
    Abu-Sbeih, Hamzah
    Ali, Faisal S.
    Naqash, Abdul Rafeh
    Owen, Dwight H.
    Patel, Sandipkumar
    Otterson, Gregory A.
    Kendra, Kari
    Ricciuti, Biagio
    Chiari, Rita
    De Giglio, Andrea
    Sleiman, Joseph
    Funchain, Pauline
    Wills, Beatriz
    Zhang, Jiajia
    Naidoo, Jarushka
    Philpott, Jessica
    Gao, Jianjun
    Subudhi, Sumit K.
    Wang, Yinghong
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (30) : 2738 - +
  • [3] Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
    Brahmer, Julie R.
    Lacchetti, Christina
    Schneider, Bryan J.
    Atkins, Michael B.
    Brassil, Kelly J.
    Caterino, Jeffrey M.
    Chau, Ian
    Ernstoff, Marc S.
    Gardner, Jennifer M.
    Ginex, Pamela
    Hallmeyer, Sigrun
    Chakrabarty, Jennifer Holter
    Leighl, Natasha B.
    Mammen, Jennifer S.
    McDermott, David F.
    Naing, Aung
    Nastoupil, Loretta J.
    Phillips, Tanyanika
    Porter, Laura D.
    Puzanov, Igor
    Reichner, Cristina A.
    Santomasso, Bianca D.
    Seigel, Carole
    Spira, Alexander
    Suarez-Almazor, Maria E.
    Wang, Yinghong
    Weber, Jeffrey S.
    Wolchok, Jedd D.
    Thompson, John A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (17) : 1714 - +
  • [4] CAMERON JS, 1988, Q J MED, V66, P97
  • [5] A new expression of immune checkpoint inhibitors' renal toxicity: when distal tubular acidosis precedes creatinine elevation
    Charmetant, Xavier
    Teuma, Cecile
    Lake, Jennifer
    Dijoud, Frederique
    Frochot, Vincent
    Deeb, Abbas
    [J]. CLINICAL KIDNEY JOURNAL, 2020, 13 (01) : 42 - 45
  • [6] Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors
    Cortazar, Frank B.
    Marrone, Kristen A.
    Troxell, Megan L.
    Ralto, Kenneth M.
    Hoenig, Melanie P.
    Brahmer, Julie R.
    Le, Dung T.
    Lipson, Evan J.
    Glezerman, Ilya G.
    Wolchok, Jedd
    Cornell, Lynn D.
    Feldman, Paul
    Stokes, Michael B.
    Zapata, Sarah A.
    Hodi, F. Stephen
    Ott, Patrick A.
    Yamashita, Michifumi
    Leaf, David E.
    [J]. KIDNEY INTERNATIONAL, 2016, 90 (03) : 638 - 647
  • [7] Immune checkpoint inhibitor rechallenge in patients with immune-related myositis
    Delyon, Julie
    Brunet-Possenti, Florence
    Leonard-Louis, Sarah
    Arangalage, Dimitri
    Baudet, Mathilde
    Baroudjian, Barouyr
    Lebbe, Celeste
    Hervier, Baptiste
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 (11)
  • [8] Foreword
    Eckardt, Kai-Uwe
    Kasiske, Bertram L.
    [J]. KIDNEY INTERNATIONAL SUPPLEMENTS, 2012, 2 (01) : 7 - 7
  • [9] Renal Tubular Acidosis an Adverse Effect of PD-1 Inhibitor Immunotherapy
    El Bitar, Sandy
    Weerasinghe, Chanudi
    El-Charabaty, Elie
    Odaimi, Marcel
    [J]. CASE REPORTS IN ONCOLOGICAL MEDICINE, 2018, 2018
  • [10] Anti-CTLA4 Antibody-Induced Lupus Nephritis.
    Fadel, Fouad
    El Karoui, Khalil
    Knebelmann, Bertrand
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (02) : 211 - 212